What's new in lung pathology: Minutes from the pulmonary pathology working group of the German Society of Pathology;Neues zur Lungenpathologie: Bericht der Arbeitsgemeinschaft Pneumopathologie der Deutschen Gesellschaft für Pathologie

Pathologe

Volumn 32, Issue SUPPL.2, 2011, Pages 351-357

  Petersen, I ^a   Schnabel, P A ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Classification; Lung cancer; Molecular marker; Pathology; Targeted therapy

Indexed keywords

ANIMAL; ARTICLE; HUMAN; LUNG DISEASE;

ANIMALS; HUMANS; LUNG DISEASES;

EID: 80755175749     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-011-1512-5     Document Type: Article

References (31)

1. Balda MS, Matter K (2003) Epithelial cell adhesion and the regulation of gene expression. Trends Cell Biol 13(6):310-318 (Pubitemid 36638798)
2. Balda MS, Matter K (2009) Tight junctions and the regulation of gene expression. Biochim Biophys Acta 1788(4):761-767
3. Banerjee AK (2009) Preinvasive lesions of the bronchus. J Thorac Oncol 4(4):545-551. doi: 10.1097/JTO.0b013e31819667bd
4. Bossard C, Jarry A, Colombeix C, et al. (2006) Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol 59(7):706-710 (Pubitemid 44048778)
5. Chen Y, Cui T, Yang L, et al. (2011) The diagnostic value of Cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer. Oncology 80:333-340. DOI:10.1159/000329098.
6. Choi YL, Soda M, Yamashita Y, et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734-1739
7. Cui T, Chen Y, Yang L, et al. (2011a) DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br J Cancer 104(6):1013-1019
8. Cui T, Chen Y, Knösel T, et al. (2011b) Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol 39(1):161-168. doi: 10.3892/ijo.2011.1010.
9. Diederichs S (2010) Nichtkodierende RNA in malignen Tumoren. Eine neue Welt von Tumor-Biomarkern und Zielstrukturen in Krebszellen. Pathologe 31(Suppl 2):258-262
10. Fisseler-Eckhoff A (2009) Sitzungsbericht der AG Pneumopathologie der DGP (Freiburg, 7.6.2009). Pathologe 30 (Suppl 2):239-240
11. Hamidov Z, Altendorf-Hofmann A, Chen Y, et al. (2011) Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J Clin Pathol [Epub ahead of print]
12. Hammerman PS, Sos ML, Ramos AH, et al. (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1): 78-89. doi:10.1158/2159-8274.CD-11-0005
13. Jonigk D, Theophile K, Hussein K, et al. (2010) Obliterative airway remodelling in transplanted and non-transplanted lungs. Virchows Arch 457(3):369-380
14. Jonigk D, Merk M, Hussein K, et al. (2011) Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol 178(2):599-608.
15. Jonigk D, Golpon H, Bockmeyer CL, et al. (2011) Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 179(1):167-179
16. Kwak EL, Bang YJ, Camidge DR, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693-1703. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588
17. Lovly CM, Heuckmann JM, Stanchina E de, et al. (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71(14):4920-4931
18. Mino-Kenudson M, Chirieac LR, Law K, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16(5):1561-1571
19. Nitsche K, Günther B, Katenkamp D, Petersen I (2011) Thoracic neoplasms at the Jena Reference Center for Soft Tissue Tumors. Manuskript eingereicht
20. Petersen I (2010) Morphologische und molekulare Pathologie des Lungenkarzinoms. Pathologe 31(Suppl 2):204-210
21. Querings S, Altmüller J, Ansén S, et al. (2011) Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 6(5):e19601
22. Salaün M, Sesboüé R, Moreno-Swirc S, et al. (2008) Molecular predictive factors for progression of high-grade preinvasive bronchial lesions. Am J Respir Crit Care Med 177(8):880-886 (Pubitemid 351600666)
23. Salaün M, Bota S, Thiberville L (2009) Long-term follow-up of severe dysplasia and carcinoma in situ of the bronchus. J Thorac Oncol 4(9):1187-1188
24. Travis WD, Brambilla E, Noguchi M, et al. (2011) International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244-285
25. Warth A, Muley T, Herpel E, et al. (2011) Large scale comparative analyses of immunomarkers for diagnostic subtyping of non-small cell lung cancer biopsies. Manuskript eingereicht
26. Weihmann J, Petersen I, Gajda M (2011) Evaluation eines Zellblock-Verfahrens in der zytologischen Diagnostik. Manuskript in Bearbeitung
27. Weiss J, Sos ML, Seidel D, et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2(62):62ra93. Erratum in: Sci Transl Med.3(66):66er2
28. Wilusz JE, Sunwoo H, Spector DL (2009) Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 23(13):1494-1504
29. Winter J, Diederichs S (2011) MicroRNA biogenesis and cancer. Methods Mol Biol 676:3-22
30. Yatabe Y, Borczuk AC, Powell CA (2011) Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer [Epub ahead of print]
31. Zahel T, Krysa S, Herpel E, et al. (2011) Phenotyping of pulmonary carcinoids and proposal of a grading system. Manuskript eingereicht